TCT

This channel contains news about the annual Transcatheter Cardiovascular Therapeutics (TCT) conference presented by the Cardiovascular Research Foundation (CRF). It includes coverage from the annual meeting and links CRF news. TCT is the premier conference for the subspecialty of interventional cardiology, including the new subspecialty areas of transcatheter structural heart procedures. 

Six Months of DAPT Non-Inferior to Twelve in STEMI Patients Receiving Drug-Eluting Stents. Photo courtesy of Siemens Healthineers

Photo courtesy of Siemens Healthineers

News | Antiplatelet and Anticoagulation Therapies | November 06, 2017
November 6, 2017 —  The first trial to evaluate the safety of dual antiplatelet therapy (DAPT) for less than 12 months...
FAME2 cost effectiveness of FFR guided PCI vs. medical therapy alone. TCT 2017

FAME2 cost effectiveness of FFR guided PCI vs. medical therapy alone.

News | FFR Technologies | November 06, 2017
November 6, 2017 — Three-year data from the FAME 2 study show patients with coronary artery disease who underwent a...
Synergy Stent With Shorter DAPT Superior to Bare-Metal Stent in Elderly Patients
News | Stents Drug Eluting | November 06, 2017
November 6, 2017 — Elderly patients undergoing percutaneous coronary intervention (PCI) often receive bare-metal stents...
Biotronik Orsiro DES Shows Low Five-Year Event Rates
News | Stents Drug Eluting | November 03, 2017
November 3, 2017 — Biotronik's Orsiro drug-eluting stent (DES) demonstrated high long-term safety and clinical...
Acist Medical Systems Announces Approval and Launch of Next-Generation FFR System
Technology | FFR Technologies | November 03, 2017
November 3, 2017 — Acist Medical Systems Inc., a Bracco Group Company, announced the global launch of its Acist RXi...
The Watchman LAA occluder PREVAIL Trial 5-year results were presented at the 2017 TCT meeting.
Feature | Atrial Fibrillation | November 02, 2017
November 2, 2017 – Five-year results from the PREVAIL Trial comparing left atrial appendage closure (LAAC) with the...
The B. Braun Sequent Please drug-eluting balloon.

An illustration of the Sequent Please drug-coated balloon.

Feature | Drug-Eluting Balloons | November 02, 2017
November 2, 2017 — The treatment of in-stent restenosis (ISR) remains challenging in clinical practice. The DARE (Drug-...
Study Examines Use of CrossBoss Catheter for Chronic Total Occlusion PCI
News | Chronic Total Occlusion (CTO) | November 02, 2017
November 2, 2017 — Crossing the occlusion with a guidewire is often the most challenging part of chronic total...
Three-Month DAPT Non-Inferior for ACS Patients Treated With Combo Dual Therapy Stent

Image courtesy of OrbusNeich

News | Stents Drug Eluting | November 01, 2017
November 1, 2017 — OrbusNeich reported results from the REDUCE trial in the Late-Breaking Clinical Trial session at the...
Double Kissing Crush Two-Stent Technique in Left Main Bifurcation Lesions Demonstrates Lower Target Lesion Failure Rates
News | Stents Bifurcation | November 01, 2017
November 1, 2017 — The double kissing (DK) crush two-stent technique was associated with a lower rate of target lesion...
Analytics 4 Life Presents Clinical Data on Machine-Learned Cardiac Imaging Technology at TCT 2017
News | Cardiac Diagnostics | November 01, 2017
November 1, 2017 — Analytics 4 Life announced it will be presenting new clinical data on the company's ongoing Coronary...
TAVR Cost-Effective Compared With SAVR in Intermediate-Risk Aortic Stenosis Patients
News | Heart Valve Technology | November 01, 2017
November 1, 2017 — Analysis of the PARTNER 2A trial and the SAPIEN-3 Intermediate Risk registry found transcatheter...
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab | November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strategy...
The Boston Scientific FilterWire EZ embolic protec filter system.

The Boston Scientific FilterWire EZ embolic protection system.

News | Embolic Protection Devices | October 31, 2017
October 31, 2017 — The VAMPIRE 3 study evaluated if the selective use of distal filter protection might decrease the...
Sapien 3 Valve Demonstrates Significant Cost Savings Over Surgery In Intermediate-Risk Patients
News | Heart Valve Technology | October 31, 2017
October 31, 2017 — Edwards Lifesciences Corp. announced new data demonstrating substantial economic advantages of the...